Hyperlipoproteinaemia(a) is a common cause of autosomal dominant hypercholesterolaemia

Journal of Inherited Metabolic Disease

Volumn 30, Issue 6, 2007, Pages 970-977

  Merino Ibarra E ^a   Puzo, J ^b   Jarauta, E ^a   Cenarro, A ^a   Recalde, D ^a   Garcia Otin A L ^a   Ros, E ^c   Martorell, E ^d   Pinto X ^e   Franco, M ^f   Zambon D ^c   Brea, A ^g   Pocovi M ^h   Civeira, F ^a  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^b HOSPITAL SAN JORGE   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d HOSPITAL SON LLÀTZER   (Spain)

^e HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^f HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^g HOSPITAL SAN PEDRO   (Spain)

^h UNIVERSITY OF ZARAGOZA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; TRIACYLGLYCEROL;

ADULT; ARTICLE; AUTOSOMAL DOMINANT DISORDER; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC RISK; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; SPAIN;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; FEMALE; GENES, DOMINANT; HUMANS; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIAS; LIPIDS; MALE; MIDDLE AGED; PROTEIN ISOFORMS; RECEPTORS, LDL; RISK FACTORS; SPAIN;

EID: 37249048887     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-007-0585-z     Document Type: Article

References (43)

1. Abifadel M, Varret M, Rabes JP, et al (2003) Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 34: 154-156.
2. Allard D, Amsellem S, Abifadel M, et al (2005) Novel mutations in the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia. Hum Mutat 26: 497-507.
3. Ariyo AA, Thach Ch, Tracy R, for the Cardiovascular Health Study Investigators (2003) Lp(a) lipoprotein, vascular disease, and mortality in the elderly. N Engl J Med 349: 2108-2115.
4. Berg K (1963) A new serum type system in man: The Lp system. Acta Pathol Microbiol Scand 59: 369-382.
5. Bhatnagar D, Morgan J, Siddiq S, Mackness MI, Miller JP, Durrington PN (2000) Outcome of case finding among relatives of patients with known heterozygous familial hypercholesterolaemia. BMJ 321: 1-5.
6. Bowden JF, Pritchard PH, Hill JS, Frohlich JJ (1994) Lp(a) concentration and apo(a) isoform size. Relation to the presence of coronary artery disease in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 14: 1561-1568.
7. Cantin B, Gagnon F, Moorjani S (1998) Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study. J Am Coll Cardiol 31: 519-525.
8. Castillo S, Tejedor D, Mozas P, et al (2002) The apolipoprotein B R3500Q gene mutation in Spanish subjects with a clinical diagnosis of familial hypercholesterolemia. Atherosclerosis 165: 127-135.
9. Dahlen GH (1990) Incidence of Lp(a) among population. In: Scanu AM, ed. Lipoprotein(a). New York: Academic Press, 151-173.
10. Dahlen GH (1992) Potential significance of Lp(a) lipoprotein: Clinical and methodological aspects. In: Bearn AG, eds. Genetics of Coronary Heart Disease. Oslo: Institute of Medical Genetics, University of Oslo, 75-88.
11. Damgaard D, Larsen ML, Nissen PH, et al (2005) The relationship of molecular genetic to clinical diagnosis of familial hypercholesterolemia in a Danish population. Atherosclerosis 80: 155-160.
12. Danesh J, Collins R, Peto R (2000) Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 104: 1108-11013.
13. Ejarque I, Real JT, Ascaso JF, et al (2004) Estudio de los valores plasmáticos de Lp(a) en el defecto familiar de unión de la apo B 100 en una población mediterránea del sur de Europa. An Med Int (Madrid) 21: 322-325.
14. Elisaf M, Bairaktari H, Siamopoulos KC (1996) Lp(a) levels in Greek patients with heterozygous familial hypercholesterolemia. Int J Cardiol 53: 314-316.
15. Gaw A, Murray HM, Brown EA, the PROSPER Study Group (2005) Plasma lipoprotein(a) [Lp(a)] concentrations and cardiovascular events in the elderly: Evidence from the prospective study of pravastatin in the elderly at risk (PROSPER). Atherosclerosis 180: 381-388.
16. Gomez-Gerique JA, Gutierrez-Fuentes JA, Montoya MT, et al (1999) Lipid profile of the Spanish population: The DRECE (Diet and Risk of Cardiovascular Disease in Spain) study. DRECE study group. Med Clin (Barc) 13: 730-735.
17. Graham CA, McIlhatton BP, Kirk CW, et al (2005) Genetic screening protocol for familial hypercholesterolemia which includes splicing defects gives an improved mutation rate. Atherosclerosis 182: 331-340.
18. Grebe MT, Schoene E, Schaefer CA, et al (2007) Elevated lipoprotein(a) does not promote early atherosclerotic changes of the carotid arteries in young, healthy adults. Atherosclerosis 190: 194-198.
19. Hadfield SG, Humphries SE (2005) Implementation of cascade testing for the detection of familial hypercholesterolaemia. Curr Opin Lipidol 16: 428-433.
20. Heath K, Day IN, Humpries SE (2000) Universal primer quantitative fluorescent multiplex (UPQFM) PCR: A method to detect major and minor rearrangements of the low density lipoprotein receptor gene. J Med Genet 37: 272-280.
21. Holmes DT, Schick BA, Humphries KH, Frohlich J (2005) Lipoprotein(a) is an independent risk factor for cardiovascular disease in heterozygous familial hypercholesterolemia. Clin Chem 51: 2067-2073.
22. Hopkins PN, Stephenson S, Wu LL, Riley WA, Xin Y, Hunt SC (2001) Evaluation of coronary risk factors in patients with heterozygous familial hypercholesterolemia. Am J Cardiol 87: 547-553.
23. Jansen AC, van Aalst-Cohen ES, Tanck MW, et al (2004) The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: Data in 2400 patients. J Intern Med 256: 482-490.
24. Jenner JL, Ordovas JM, Lamon-Fava S, et al (1993) Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels. The Framingham Offspring Study. Circulation 87: 1135-1141.
25. Kastelein JJP, Fouchier SW, Defesche JC (2005) What promise does PCSK9 hold? JACC 45 (10): 1620-1621.
26. Kraft HG, Lingenhel A, Raal FJ, Hohenegger M, Utermann G (2000) Lipoprotein(a) in homozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 20: 522-528.
27. Kronenberg F, Kronenberg MF, Kiechl S, et al (1999) Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis. Prospective results from the Bruneck Study. Circulation 100: 1154-1160.
28. Li KM, Wilcken DEL, Dudman NPB (1994) Effect of serum lipoprotein(a) on estimation of low-density lipoprotein cholesterol by the Friedwald formula. Clin Chem 40: 571-573.
29. Marcovina SM, Albers JJ, Wijsman E, Zhang Z, Chapman NH, Kennedy H (1996) Differences in Lp[a] concentration and apo[a] polymorphs between black and white Americans. J Lipid Res 37: 2569-2585.
30. Marcovina SM, Koschinsky ML, Albers JJ, Skarlatos S (2003) Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: Recent advances and future directions. Clin Chem 49: 1785-1796.
31. Mbewu AD, Bhatnagar D, Durrington PN, et al (1991) Serum lipoprotein(a) in patients heterozygous for familial hypercholesterolemia, their relatives, and unrelated control populations. Arterioscler Thromb Vasc Biol 11: 940-946.
32. Merino-Ibarra E, Castillo S, Mozas P, et al (2005) Screening of APOB gene mutations in subjects with clinical diagnosis of familial hypercholesterolemia. Hum Biol 5: 663-673.
33. Morita Y, Himeno H, Yakuwa H, Usui T (2006) Serum lipoprotein(a) level and clinical coronary stenosis progression in patients with myocardial infarction. Re-revascularization rate is high in patients with high Lp(a). Circ J 70: 156-162.
34. Nassir F, Bonen DK, Davidson NO (1998) Apolipoprotein(a) synthesis and secretion from hepatoma cells is coupled to triglyceride synthesis and secretion. J Biol Chem 273: 17793-17800.
35. Neil HA, Seagroatt V, Betteridge DJ, et al (2004) Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia. Heart 90: 1431-1437.
36. Pocovi M, Civeira F, Alonso R, Mata P (2004) Familial hypercholesterolemia in Spain: Case-finding program, clinical and genetic aspects. Semin Vasc Med 4: 67-74.
37. Rader DJ, Mann WA, Cain W, et al (1995) The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans. J Clin Invest 95: 1403-1408.
38. Rader DJ, Cohen J, Hobbs HH (2003) Monogenic hypercholesterolemia: New insights in pathogenesis and treatment. J Clin Invest 111: 1795-1803.
39. Tejedor D, Castillo S, Mozas P, et al (2005) Reliable low-density DNA array based on allele-specific probes for detection of 118 mutations causing familial hypercholesterolemia. Clin Chem 51: 1137-1144.
40. Utermann G, Hoppichler F, Dieplinger H, Seed M, Thompson G, Boerwinkle E (1989) Defects in the low density lipoprotein receptor gene affect lipoprotein (a) levels: Multiplicative interaction of two gene loci associated with premature atherosclerosis. Proc Natl Acad Sci USA 86: 4171-4174.
41. Utermann G (2001) Lipoprotein(a). In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds; Childs B, Kinzler KW, Vogelstein B, assoc. eds. The Metabolic and Molecular Bases of Inherited Disease, 8th edn. New York: McGraw-Hill, 2753-2787.
42. White AL, Hixson JE, Rainwater DL, Lanford RE (1994) Molecular basis for 'null' lipoprotein(a) phenotypes and the influence of apolipoprotein(a) size on plasma lipoprotein(a) level in the baboon. J Biol Chem 269: 9060-9066.
43. Wiklund O, Angelin B, Olofsson SO, et al (1990) Apolipoprotein(a) and ischaemic heart disease familial hypercholesterolaemia. Lancet 335: 1360-1363.